NL-1

CAS No. 188532-26-5

NL-1( —— )

Catalog No. M21575 CAS No. 188532-26-5

NL-1 is a mitoNEET inhibitor with antileukemic effect.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 55 Get Quote
25MG 113 Get Quote
50MG 194 Get Quote
100MG 292 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    NL-1
  • Note
    Research use only, not for human use.
  • Brief Description
    NL-1 is a mitoNEET inhibitor with antileukemic effect.
  • Description
    NL-1 is a mitoNEET inhibitor with antileukemic effect.
  • In Vitro
    NL-1 (10-100 μM; 72 hours; REH, REH/Ara-C and ALL cell lines) treatment reduces the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner. NL-1 inhibits SUPB15, NALM6 with IC50s of 29.48 μM, 94.26 μM, respectively. TOM1, BV173, NALM1 and JM1 all have similar IC50 values of around 60 μM for NL-1. NL-1 (60 μM; 6 hours; REH, REH/Ara-C cell lines) treatment mediates autophagy, and inhibition of autophagy partially decreased NL-1-induced tumor cell death.NL-1 pretreatment inhibits the chemotactic ability of both REH and REH/Ara-C cells to migrate towards multiple chemoattractants. The cells treated with NL1 shows a dose-dependent decrease in chemotaxis both in the REH and the REH/AraC cells. Cell Proliferation Assay Cell Line:REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines Concentration:10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, 100 μM Incubation Time:72 hours Result:Reduced the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner.Cell Autophagy Assay Cell Line:REH, REH/Ara-C cell lines Concentration:60 μM Incubation Time:6 hours Result:Induced cell autophagy.
  • In Vivo
    NL-1 (10 mg/kg; intraperitoneal injection; daily; for 5 days; female NSG mice) treatment shows antileukemic activity in an in vivo mouse ALL model. Animal Model:10 female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (6-8 month old) injected with TOM-1 ALL cells Dosage:10 mg/kg Administration:Intraperitoneal injection; daily; for 5 days Result:Showed antileukemic activity in an in vivo mouse ALL model.
  • Synonyms
    ——
  • Pathway
    Autophagy
  • Target
    Autophagy
  • Recptor
    mitoNEET
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    188532-26-5
  • Formula Weight
    335.46
  • Molecular Formula
    C18H25NO3S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:250 mg/mL (745.25 mM; Need ultrasonic)
  • SMILES
    CC(C)(C)c1cc(CC2SC(=O)NC2=O)cc(c1O)C(C)(C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Geldenhuys WJ et al. The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia. J Pharmacol Exp Ther. 2019 Jul;370(1):25-34.
molnova catalog
related products
  • Thymosin β4 acetate(...

    Thymosin β4 (Tβ4) is a thymic hormone with multiple and different intracellular and extracellular activities affecting wound healing, inflammation, fibrosis and tissue regeneration.

  • 2,2-Dihydroxy chalco...

    2,2'-Dihydroxy chalcone is a potent inhibitor of β-glucuronidase (IC50=1.6±0.2 μM) and lysozyme (IC50=1.4±0.2 μM) release from rat neutrophils stimulated with fMLP/CB.2,2'-Dihydroxy chalcone has inhibitory activity against Escherichia coli, Shigella fowleri, Staphylococcus albicans and Staphylococcus aureus.

  • Vitamin B3-d4

    Vitamin B3-d4 (Nicotinic acid-(ring-d4)) is the deuterium substitute for Niacin and is used to track Niacin metabolism in the body.